

December 2, 2015



## Trevena to present at the Oppenheimer 26th Annual Healthcare Conference

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company will be webcasting its corporate presentation at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8, 2015 at 1:00 p.m. EST in New York.

To access the live audio webcast of the presentation, please visit the "Investors" section of the Company's website at [www.trevenainc.com](http://www.trevenainc.com). Following the conclusion of the presentation, the webcast will be archived for 30 days.

### About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena is developing four biased ligand product candidates it has identified – TRV027 to treat acute heart failure (Phase 2b), TRV130 to treat moderate to severe acute pain intravenously (completed Phase 2), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for acute episodic migraine and other CNS disorders (preclinical).

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20151202006042/en/>

### Investor Contacts:

Trevena, Inc.

Jonathan Violin

Director of investor relations

610-354-8840 x231

[jviolin@trevenainc.com](mailto:jviolin@trevenainc.com)

or

Argot Partners

Andrea Rabney

President and chief executive officer

212-600-1902

[andrea@argotpartners.com](mailto:andrea@argotpartners.com)

or

### Media Contact:

Argot Partners

Eliza Schleifstein

917-763-8106

[eliza@argotpartners.com](mailto:eliza@argotpartners.com)

Source: Trevena, Inc.